Tonix Pharmaceuticals Holding Corp. (TNXP) stock
Close on Nov 12, 2026Market cap $55.57MP/E –Yield –
Tonix Pharmaceuticals Holding Corp. grew revenue 318.0% to $43.05M over the twelve months to Sep 30, 2026. Free cash flow was -$170.04M. At the latest close the market valued the company at $55.57M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $55.57M
- P/E ratio
- –
- Price to sales
- 1.29
- Price to book
- 0.28
- Dividend yield
- –
- Free cash flow yield
- -306.00%
Fundamentals
- Revenue
- $43.05M
- Net income
- -$180.99M
- EPS, diluted
- -$12.22
- Free cash flow
- -$170.04M
- Book value per share
- $10.82
- Diluted shares
- 18M
Trading
- Next earnings
- Mar 12, 2027 (estimated, before the open)
- Previous close
- $3.87
- Open
- $3.96
- Day's range
- $3.21 – $3.96
- Volume
- 2,454,547
- Average volume (20 days)
- 1,025,831
- Index membership
- Russell 2000 (since Jun 2025)
- Beta (5 years)
- 2.04
- 52-week range
- $3.21 – $20.56
- RSI (14 days)
- 12.3
- Volatility (1 year)
- 73.7%
- Relative volume
- 3.61×
- WACC
- 15.1%
On 2 of our idea lists: Net-nets, More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2012, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | TNXP | S&P 500 | Difference | TNXP per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -51.2% | -2.7% | −48.5 pts | ||
| 3 months | -72.9% | -1.7% | −71.2 pts | ||
| Year to date | -79.3% | +11.9% | −91.2 pts | ||
| 1 year | -81.7% | +12.0% | −93.7 pts | ||
| 3 years | -99.8% | +78.2% | −178.0 pts | -87.1% | +21.2% |
| 5 years | -100.0% | +73.2% | −173.2 pts | -90.1% | +11.6% |
| 10 years | -100.0% | +309.6% | −409.6 pts | -83.9% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Tonix Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- News
- Results
- Update
- Update
About Tonix Pharmaceuticals
Pharmaceutical Preparations
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company that commercializes and develops therapies for central nervous system disorders, immunology, infectious diseases, and rare diseases. Its commercial product portfolio features TONMYA, a sublingual tablet formulation for treating fibromyalgia in adults, as well as Zembrace SymTouch and Tosymra, both indicated for the treatment of acute migraine. The company's development pipeline encompasses multiple clinical- and preclinical-stage candidates targeting indications such as acute stress disorder, major depressive disorder, organ transplant rejection, cocaine intoxication, and Prader-Willi syndrome.
Company profile, executives and historyTonix Pharmaceuticals stock: common questions
What is Tonix Pharmaceuticals's stock price?
TNXP closed at $3.24 on Nov 12, 2026, down 16.28% on the day. Over the past 52 weeks it traded between $3.21 and $20.56.
What is Tonix Pharmaceuticals's market cap?
Tonix Pharmaceuticals was worth $55.57M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is TNXP's P/E ratio?
Tonix Pharmaceuticals lost money over the twelve months to Sep 30, 2026 (diluted EPS -$12.22), so it has no meaningful P/E ratio.
How much revenue does Tonix Pharmaceuticals make?
Tonix Pharmaceuticals reported revenue of $43.05M for the twelve months to Sep 30, 2026, up 318.0% from a year earlier.
Does Tonix Pharmaceuticals pay a dividend?
No. Tonix Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Tonix Pharmaceuticals report earnings next?
Tonix Pharmaceuticals is expected to report Q4 FY2026 results on Mar 12, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has TNXP stock performed over the past year?
Including dividends, TNXP returned -81.7% over the past year, against +12.0% for the S&P 500.
How many TNXP shares are sold short?
3M shares were sold short at the latest FINRA report, 19.40% of the float, or 4.1 days of average trading volume.
Who are Tonix Pharmaceuticals's competitors?
Companies most similar to Tonix Pharmaceuticals by business, industry and size include AYTU, LXRX, OCUL, AQST, ROIV.
See a number that looks wrong?